Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent.

Johnson L, O'Donoghue JM, McLean N, Turton P, Khan AA, Turner SD, Lennard A, Collis N, Butterworth M, Gui G, Bristol J, Hurren J, Smith S, Grover K, Spyrou G, Krupa K, Azmy IA, Young IE, Staiano JJ, Khalil H, MacNeill FA.

Eur J Surg Oncol. 2017 Aug;43(8):1393-1401. doi: 10.1016/j.ejso.2017.05.004. Epub 2017 May 18.

PMID:
28596034
2.

Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.

Bilger A, Plowshay J, Ma S, Nawandar D, Barlow EA, Romero-Masters JC, Bristol JA, Li Z, Tsai MH, Delecluse HJ, Kenney SC.

Oncotarget. 2017 Jul 4;8(27):44266-44280. doi: 10.18632/oncotarget.17863.

3.

SYN-004 (ribaxamase), an oral beta-lactamase, mitigates antibiotic-mediated dysbiosis in a porcine gut microbiome model.

Connelly S, Bristol JA, Hubert S, Subramanian P, Hasan NA, Colwell RR, Kaleko M.

J Appl Microbiol. 2017 Feb 28. doi: 10.1111/jam.13432. [Epub ahead of print]

PMID:
28245091
4.

Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential.

Ma SD, Tsai MH, Romero-Masters JC, Ranheim EA, Huebner SM, Bristol JA, Delecluse HJ, Kenney SC.

J Virol. 2017 Mar 13;91(7). pii: e01928-16. doi: 10.1128/JVI.01928-16. Print 2017 Apr 1.

5.

Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies.

Roberts T, Kokai-Kun JF, Coughlin O, Lopez BV, Whalen H, Bristol JA, Hubert S, Longstreth J, Lasseter K, Sliman J.

Clin Drug Investig. 2016 Sep;36(9):725-734. doi: 10.1007/s40261-016-0420-0.

PMID:
27283946
6.

Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection.

Kaleko M, Bristol JA, Hubert S, Parsley T, Widmer G, Tzipori S, Subramanian P, Hasan N, Koski P, Kokai-Kun J, Sliman J, Jones A, Connelly S.

Anaerobe. 2016 Oct;41:58-67. doi: 10.1016/j.anaerobe.2016.05.015. Epub 2016 Jun 2.

7.

Nonclinical Safety Assessment of SYN-004: An Oral β-lactamase for the Protection of the Gut Microbiome From Disruption by Biliary-Excreted, Intravenously Administered Antibiotics.

Kokai-Kun JF, Bristol JA, Setser J, Schlosser M.

Int J Toxicol. 2016 May;35(3):309-16. doi: 10.1177/1091581815623236. Epub 2015 Dec 23.

PMID:
26700136
8.

Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells.

Sun X, Bristol JA, Iwahori S, Hagemeier SR, Meng Q, Barlow EA, Fingeroth JD, Tarakanova VL, Kalejta RF, Kenney SC.

J Virol. 2013 Sep;87(18):10126-38. doi: 10.1128/JVI.01671-13. Epub 2013 Jul 10.

9.

Let's keep clinical breast examination until the breast service is reconfigured.

Bristol JB.

BMJ. 2012 Nov 7;345:e7422. doi: 10.1136/bmj.e7422. No abstract available.

PMID:
23135223
10.

The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins.

Bristol JA, Robinson AR, Barlow EA, Kenney SC.

J Virol. 2010 Dec;84(23):12362-74. doi: 10.1128/JVI.00712-10. Epub 2010 Sep 22.

11.

Education and imaging. Gastrointestinal: lipoma induced intussusception of the transverse colon.

Mason R, Bristol JB, Petersen V, Lyburn ID.

J Gastroenterol Hepatol. 2010 Jun;25(6):1177. doi: 10.1111/j.1440-1746.2010.06360.x. No abstract available.

PMID:
20594237
12.

Hyperendemic H. pylori and tapeworm infections in a U.S.-Mexico border population.

Cardenas VM, Mena KD, Ortiz M, Karri S, Variyam E, Behravesh CB, Snowden KF, Flisser A, Bristol JR, Mayberry LF, Ortega YR, Fukuda Y, Campos A, Graham DY.

Public Health Rep. 2010 May-Jun;125(3):441-7.

13.

CCAAT/enhancer binding proteins alpha and beta regulate the tumor necrosis factor receptor 1 gene promoter.

Bristol JA, Morrison TE, Kenney SC.

Mol Immunol. 2009 Aug;46(13):2706-13. doi: 10.1016/j.molimm.2009.05.024. Epub 2009 Jun 11.

14.

Population-based survey of taeniasis along the United States-Mexico border.

Barton Behravesh C, Mayberry LF, Bristol JR, Cardenas VM, Mena KD, Martínez-Ocaña J, Flisser A, Snowden KF.

Ann Trop Med Parasitol. 2008 Jun;102(4):325-33. doi: 10.1179/136485908X300788.

PMID:
18510813
15.

Occurrence of faecal contamination in households along the US-Mexico border.

Carrasco L, Mena KD, Mota LC, Ortiz M, Behravesh CB, Gibbs SG, Bristol JR, Mayberry L, Cardenas VM.

Lett Appl Microbiol. 2008 Jun;46(6):682-7. doi: 10.1111/j.1472-765X.2008.02378.x. Epub 2008 May 10.

16.

Suppression of extraintestinal and intestinal Nippostrongylus brasiliensis-induced eosinophilia by Eimeria nieschulzi.

Al-Dahwi Z, Mayberry LF, Conder GA, Bristol JR.

J Parasitol. 2006 Oct;92(5):962-70.

PMID:
17152935
17.

Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.

Zhu M, Bristol JA, Xie Y, Mina M, Ji H, Forry-Schaudies S, Ennist DL.

J Virol. 2005 May;79(9):5455-65.

18.

Breast metastases from colorectal carcinoma.

Mihai R, Christie-Brown J, Bristol J.

Breast. 2004 Apr;13(2):155-8.

PMID:
15019699
19.

Potentiation of oncolytic adenoviral vector efficacy with gutless vectors encoding GMCSF or TRAIL.

Burroughs KD, Kayda DB, Sakhuja K, Hudson Y, Jakubczak J, Bristol JA, Ennist D, Hallenbeck P, Kaleko M, Connelly S.

Cancer Gene Ther. 2004 Feb;11(2):92-102.

PMID:
14730331
20.

The effects of childhood sexual abuse on adherence and health.

Curry M, Bristol J.

Focus. 2003 Apr;18(5):5-6. No abstract available.

PMID:
12866481
21.

In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF.

Bristol JA, Zhu M, Ji H, Mina M, Xie Y, Clarke L, Forry-Schaudies S, Ennist DL.

Mol Ther. 2003 Jun;7(6):755-64.

22.

Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.

Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, Przetak M, Chow J, Gusovsky F, Christ WJ, Rossignol DP.

J Pharmacol Exp Ther. 2003 Mar;304(3):1093-102.

24.

Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.

Bristol JA, Gallo-Penn A, Andrews J, Idamakanti N, Kaleko M, Connelly S.

Hum Gene Ther. 2001 Sep 1;12(13):1651-61.

PMID:
11535168
26.

In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice.

Bristol JA, Shirley P, Idamakanti N, Kaleko M, Connelly S.

Mol Ther. 2000 Sep;2(3):223-32.

27.

Kinetic mechanism of the p38-alpha MAP kinase: phosphoryl transfer to synthetic peptides.

Chen G, Porter MD, Bristol JR, Fitzgibbon MJ, Pazhanisamy S.

Biochemistry. 2000 Feb 29;39(8):2079-87.

PMID:
10684658
28.

Unusual findings in a patient taking warfarin.

Morgan RJ, Bristol JB.

Postgrad Med J. 1999 May;75(883):299-300. No abstract available.

29.

E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide.

Kawata T, Bristol JR, Rossignol DP, Rose JR, Kobayashi S, Yokohama H, Ishibashi A, Christ WJ, Katayama K, Yamatsu I, Kishi Y.

Br J Pharmacol. 1999 Jun;127(4):853-62.

30.

Detection of metachronous breast carcinoma: the role of follow-up?

Morgan RJ, Bristol JB.

Ann R Coll Surg Engl. 1999 Mar;81(2):97-9.

33.

Biosynthesis of prothrombin: intracellular localization of the vitamin K-dependent carboxylase and the sites of gamma-carboxylation.

Bristol JA, Ratcliffe JV, Roth DA, Jacobs MA, Furie BC, Furie B.

Blood. 1996 Oct 1;88(7):2585-93.

35.

Anti-endotoxin activity of a novel synthetic lipid A analog.

Kawata T, Bristol JR, Rose JR, Rossignol DP, Christ WJ, Asano O, Dubuc GR, Gavin WE, Hawkins LD, Kishi Y, et al.

Prog Clin Biol Res. 1995;392:499-509.

PMID:
8524958
36.

Regulation of phospholipase C-beta isozymes by G-proteins.

Bristol JA, Rhee SG.

Trends Endocrinol Metab. 1994 Dec;5(10):402-6.

PMID:
18407236
37.

Profactor IX: the propeptide inhibits binding to membrane surfaces and activation by factor XIa.

Bristol JA, Freedman SJ, Furie BC, Furie B.

Biochemistry. 1994 Nov 29;33(47):14136-43.

PMID:
7947825
38.

Fine-catheter peritoneal cytology in the management of acute abdominal pain.

Blazeby JM, Tulloh BR, Adams DC, Poskitt KR, Bristol JB.

Br J Surg. 1994 May;81(5):684. No abstract available.

PMID:
8044546
39.

Absence of typical Nippostrongylus brasiliensis self-cure in putative BALB/c mice.

Mayberry LF, Conder GA, Bristol JR, Johnson SS, Modric S.

J Parasitol. 1993 Dec;79(6):962-3.

PMID:
8277393
40.

PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway.

Wasley LC, Rehemtulla A, Bristol JA, Kaufman RJ.

J Biol Chem. 1993 Apr 25;268(12):8458-65.

41.
42.

Surgical discharge summaries: improving the record.

Adams DC, Bristol JB, Poskitt KR.

Ann R Coll Surg Engl. 1993 Mar;75(2):96-9.

43.

Autologous predonation, haemodilution and intraoperative blood salvage in elective abdominal aortic aneurysm repair.

Tulloh BR, Brakespear CP, Bates SC, Adams DC, Dalton RG, Richards MJ, Durkin MA, Bristol JB, Poskitt KR.

Br J Surg. 1993 Mar;80(3):313-5.

PMID:
8472137
44.

Effect of Eimeria nieschulzi on Nippostrongylus brasiliensis-induced IgE.

Sambrano GR, Mayberry LF, Bristol JR.

Parasitol Res. 1992;78(2):172-4. No abstract available.

PMID:
1557331
45.

N6-substituted adenosine receptor agonists: potential antihypertensive agents.

Trivedi BK, Blankley CJ, Bristol JA, Hamilton HW, Patt WC, Kramer WJ, Johnson SA, Bruns RF, Cohen DM, Ryan MJ.

J Med Chem. 1991 Mar;34(3):1043-9.

PMID:
2002448
46.

Effects of Eimeria separata on eosinophilia induced by Nippostrongylus brasiliensis.

Ramirez MT, Mayberry LF, Bristol JR.

Parasitol Res. 1991;77(4):367-8. No abstract available.

PMID:
1866428
47.

Surface immunoglobulin-positive T lymphocytes in HIV-1 infection: relationship to CD4+ lymphocyte depletion.

Ardman B, Mayer K, Bristol J, Ryan M, Settles M, Levy E.

Clin Immunol Immunopathol. 1990 Aug;56(2):249-58.

PMID:
1974180
48.

Effects on CD4 binding of anti-peptide sera to the fourth and fifth conserved domains of HIV-1 gp120.

Ardman B, Kowalski M, Bristol J, Haseltine W, Sodroski J.

J Acquir Immune Defic Syndr. 1990;3(3):206-14.

PMID:
2304000
49.
50.

Transfer of Eimeria nieschulzi using extraintestinal tissue.

Mayberry LF, Gaytán O, Bristol JR.

J Parasitol. 1989 Jun;75(3):470-2.

PMID:
2524557

Supplemental Content

Loading ...
Support Center